[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100498042":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":43,"centralContacts":47,"locations":57,"responsibleParty":85,"collaborators":87,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":25,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":72,"whyStopped":25,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Insel Gruppe AG, University Hospital Bern","OTHER",[8,17,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Parkinson's disease patients with DBS","EXPERIMENTAL","All Parkinson's disease patients with bilateral deep brain stimulation (DBS) in the subthalamic nucleus",[13,14,15,16],"Other: Dopaminergic OFF drug state","Other: DBS OFF state","Other: Dopaminergic ON drug state","Other: DBS ON state",{"label":18,"type":10,"description":19,"interventionNames":20},"Parkinson's disease patients without DBS","All Parkinson's disease patients without bilateral deep brain stimulation (DBS) in the subthalamic nucleus",[13,15],{"label":22,"type":23,"description":24,"interventionNames":25},"Healthy Controls","NO_INTERVENTION","All healthy volunteers",null,[27,31,35,39],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"Dopaminergic OFF drug state","Experiment will be performed without dopaminergic medication",[9,18],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":25},"DBS OFF state","Turning off the stimulation during experiment",[9],{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":25},"Dopaminergic ON drug state","Experiment will be performed with dopaminergic medication",[9,18],{"type":6,"name":40,"description":41,"armGroupLabels":42,"otherNames":25},"DBS ON state","Experiment will be performed with stimulation (ON condition)",[9],[44],{"name":45,"affiliation":5,"role":46},"Paul Krack, Prof.","PRINCIPAL_INVESTIGATOR",[48,53],{"name":45,"role":49,"phone":50,"phoneExt":51,"email":52},"CONTACT","31 66 4 03 71","+41","paul.krack@insel.ch",{"name":54,"role":49,"phone":55,"phoneExt":51,"email":56},"Mario Sousa, MD","31 664 23 49","mario.sousa@insel.ch",[58,70],{"facility":59,"status":60,"city":61,"state":25,"zip":62,"country":63,"countryCode":25,"cosmosGeoPoint":64,"geoPoint":69,"contacts":25},"Czech Technical University Prague","ACTIVE_NOT_RECRUITING","Prague","166 27","Czechia",{"type":65,"coordinates":66},"Point",[67,68],14.42076,50.08804,{"lat":68,"lon":67},{"facility":71,"status":72,"city":73,"state":25,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"University Hospital Inselspital, Berne","RECRUITING","Bern","3010","Switzerland","CH",{"type":65,"coordinates":78},[79,80],7.44744,46.94809,{"lat":80,"lon":79},[83,84],{"name":45,"role":49,"phone":50,"phoneExt":51,"email":52},{"name":54,"role":49,"phone":55,"phoneExt":51,"email":56},{"type":86,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[88],{"name":89,"class":6},"Czech Technical University in Prague","100498042","speech-as-biomarker-for-emotion-movement-and-cognition-in-parkinsons-disease-100498042",false,"NCT05765110","SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease","EMO-SPEECH-PD","Patients with Parkinson's Disease\n\nInclusion Criteria:\n\n* Written informed consent\n* Idiopathic PD according to the Movement Disorders Society Criteria;\n* Age of participants \\> 30 and ≤ 75 years;\n* Treatment with or without bilateral deep brain stimulation in the subthalamic nucleus;\n* Fluent in German or French\n\nExclusion Criteria:\n\n* Dysarthria caused in addition by a condition other than PD (e.g. stroke, myasthenia);\n* Clinical diagnosis of aphasia;\n* Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.).\n* Cognitive impairment (Montreal Cognitive Assessment (MoCa) \\\u003C 24\u002F30 points);\n* Depression with acute suicidal ideation\n\nHealthy Controls\n\nInclusion Criteria:\n\n* Written informed consent\n* Adults from 50-70 years old;\n* Fluent in German or French\n\nExclusion Criteria:\n\n* Diagnosis of Parkinson's disease;\n* Cognitive impairment (Montreal Cognitive Assessment (MoCa) \\\u003C 24\u002F30 points);\n* Suffering from brain disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.);\n* Clinical diagnosis of aphasia, dysarthria, and stuttering;\n* Suffering from or diagnosed with psychiatric illnesses according to DSM-V criteria",true,"ALL","30 Years","75 Years",{"count":102,"type":103},80,"ESTIMATED","INTERVENTIONAL",[106],"NA","With this study, the investigators want to investigate whether computerized speech analysis can be used to reliably and objectively detect motor, emotional, and cognitive fluctuations in Parkinson's disease patients.",[109],"Parkinson Disease",[111,112,113,114,115,116],"Speech","Emotion","Movement","Cognition","Biomarker","Automated speech analysis","2026-05-21",{"date":119,"type":120},"2026-05-22","ACTUAL",{"date":122,"type":120},"2023-01-03",{"date":124,"type":103},"2026-12-31",{"name":5,"class":6},2]